Publications by authors named "Martin F Meier"

Background: More than 30 million children worldwide have moderate acute malnutrition. Current treatments have limited effectiveness, and much remains unknown about the pathogenesis of this condition. Children with moderate acute malnutrition have perturbed development of their gut microbiota.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers studied how an underdeveloped gut microbiome contributes to undernutrition in Bangladeshi children with severe acute malnutrition (SAM) transitioning to moderate acute malnutrition (MAM).
  • They utilized advanced techniques including metabolomic, proteomic, and metagenomic analyses to understand the biological changes during this transition.
  • A controlled feeding study identified a specialized food (MDCF) that effectively improved gut bacteria and boosted growth, immune function, and other health indicators in children with MAM.
View Article and Find Full Text PDF

Therapeutic food interventions have reduced mortality in children with severe acute malnutrition (SAM), but incomplete restoration of healthy growth remains a major problem. The relationships between the type of nutritional intervention, the gut microbiota, and therapeutic responses are unclear. In the current study, bacterial species whose proportional representation define a healthy gut microbiota as it assembles during the first two postnatal years were identified by applying a machine-learning-based approach to 16S ribosomal RNA data sets generated from monthly faecal samples obtained from birth onwards in a cohort of children living in an urban slum of Dhaka, Bangladesh, who exhibited consistently healthy growth.

View Article and Find Full Text PDF

Insulin sensitizing thiazolidinediones (TZDs) are generally considered to work as agonists for the nuclear receptor peroxisome proliferative activated receptor-gamma (PPAR gamma). However, TZDs also have acute, non-genomic metabolic effects and it is unclear which actions are responsible for the beneficial pharmacology of these compounds. We have taken advantage of an analog, based on the metabolism of pioglitazone, which has much reduced ability to activate PPAR gamma.

View Article and Find Full Text PDF